Guardian Pharmacy Services, Inc. GRDN R2K
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States. The company's individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities, behavioral health facilities, and group homes. Its Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; GuardianShield Programs for LTCFs; Order Entry QA Analyzer, which utilizes real-time rules- engine technology to examine prescriptions and detect omissions and/or errors before they become a customer service problem; and Medication Spend Analyzer to break down the monthly drug spending for each of the LTCFs. Guardian Pharmacy Services, Inc. was founded in 2003 and is headquartered in Atlanta, Georgia.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Strong return on equity of 26.9%.
- Healthy ROCE of 29.4%.
- Compounding revenue at 16.8% over 5 years.
- Profit CAGR of 11.6% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GRDN Guardian Pharmacy Services, Inc. R2K | 38.74 | 46.12 | $2.45B | - | 29.41% | 26.91% | 16.81% | 11.59% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 262.74M | 275.41M | 300.04M | - | - | 329.31M | 344.33M | 377.43M | 397.62M | 336.60M |
| Cost of Revenue | - | - | - | - | - | 264.96M | 276.19M | 302.71M | 312.11M | 260.29M |
| Gross Profit | 52.19M | 55.10M | 61.29M | - | - | 64.35M | 68.15M | 74.72M | 85.50M | 76.31M |
| Operating Expenses | - | - | - | - | - | 51.34M | 55.57M | 58.37M | 54.74M | 58.63M |
| Operating Income | -6.33M | 7.93M | 17.00M | - | - | 13.01M | 12.58M | 16.35M | 30.76M | 17.68M |
| EBITDA | - | - | - | - | - | 18.54M | 18.25M | 22.63M | 37.00M | 24.42M |
| Interest Expense | - | - | - | - | - | 170.00K | 172.00K | 160.00K | 163.00K | 154.00K |
| Pretax Income | - | - | - | - | - | 13.11M | 12.59M | 16.63M | 31.10M | 18.29M |
| Tax Provision | - | - | - | - | - | 3.83M | 3.76M | 7.04M | 9.83M | 4.75M |
| Net Income | - | - | 0 | - | - | 9.45M | 9.03M | 9.82M | 20.92M | 13.29M |
| Diluted EPS | - | - | - | - | - | 0.15 | 0.14 | 0.15 | 0.33 | 0.21 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 908.91M | 1.05B | 1.23B | 1.45B |
| Cost of Revenue | - | 723.04M | 837.88M | 984.04M | 1.16B |
| Gross Profit | - | 185.87M | 208.31M | 244.37M | 292.72M |
| Operating Expenses | - | 133.88M | 167.36M | 307.29M | 220.02M |
| Operating Income | - | 51.99M | 40.95M | -62.92M | 72.70M |
| EBITDA | - | 68.15M | 58.81M | -43.43M | 96.42M |
| Interest Expense | - | 1.93M | 2.86M | 3.28M | 665.00K |
| Pretax Income | - | 49.66M | 37.72M | -66.48M | 73.42M |
| Tax Provision | - | - | 0 | 4.56M | 24.46M |
| Net Income | - | 35.42M | 23.90M | -87.29M | 49.22M |
| Diluted EPS | - | 0.58 | 0.00 | -1.77 | 0.78 |
Compounded Sales Growth
| 5 Years: | 16.81% |
| 1 Year: | 2.20% |
Compounded Profit Growth
| 5 Years: | 11.59% |
| 1 Year: | 39.00% |
Stock Price Performance
| 1 Year: | +82.99% |
| 6 Months: | +31.95% |
| 3 Months: | +15.61% |
| 1 Month: | +3.11% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 256.11M | 271.17M | 320.81M | 412.66M |
| Current Assets | - | 120.00M | 129.60M | 151.99M | 221.63M |
| Cash & Equivalents | - | 607.00K | 752.00K | 4.66M | 65.62M |
| Inventory | - | 41.44M | 36.73M | 40.55M | 43.36M |
| Receivables | - | 67.83M | 77.26M | 97.15M | 101.61M |
| Total Liabilities | - | 180.19M | 211.31M | 170.83M | 194.73M |
| Current Liabilities | - | 112.00M | 138.01M | 144.12M | 160.70M |
| Long Term Debt | 26.99M | 22.97M | 18.99M | - | - |
| Total Debt | - | 56.81M | 61.00M | 30.13M | 37.14M |
| Total Equity | - | 0 | 0 | 142.67M | 205.76M |
| Shares Outstanding | - | 60.84M | 60.84M | 63.29M | 63.32M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 48.52M | 70.82M | 57.96M | 100.25M |
| Investing Cash Flow | - | -17.90M | -13.44M | -30.41M | -32.23M |
| Financing Cash Flow | - | -45.03M | -57.23M | -23.64M | -7.07M |
| Capital Expenditure | - | -16.77M | -14.56M | -16.37M | -19.55M |
| Free Cash Flow | - | 31.75M | 56.26M | 41.59M | 80.71M |
| Net Change in Cash | - | -14.40M | 145.00K | 3.91M | 60.96M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 20.4% | 19.9% | 19.9% | 20.2% |
| Operating Margin % | - | 5.7% | 3.9% | -5.1% | 5.0% |
| Net Margin % | - | 3.9% | 2.3% | -7.1% | 3.4% |
| ROE % | - | - | - | -61.2% | 23.9% |
| ROCE % | - | 36.1% | 30.8% | -35.6% | 28.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 4.74% | 2.36M | $91.40M |
| 2 | Wellington Management Group, LLP | 3.55% | 1.77M | $68.38M |
| 3 | Blackrock Inc. | 3.53% | 1.76M | $68.04M |
| 4 | Woodline Partners LP | 2.62% | 1.31M | $50.61M |
| 5 | Brown Advisory Inc. | 2.53% | 1.26M | $48.78M |
| 6 | Vanguard Capital Management LLC | 2.46% | 1.23M | $47.48M |
| 7 | Valiant Capital Management, L.P. | 2.38% | 1.19M | $45.97M |
| 8 | Times Square Capital Management, LLC | 2.16% | 1.08M | $41.74M |
| 9 | T. Rowe Price Investment Management, Inc. | 2.07% | 1.03M | $39.84M |
| 10 | Boston Partners | 2.04% | 1.02M | $39.43M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GRDN